# A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

> **NCT04684394** · PHASE2 · TERMINATED · sponsor: **Gemini Therapeutics, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Retinal Disease
- Retinal Degeneration
- Macular Degeneration

## Interventions

- **BIOLOGICAL:** GEM103
- **DRUG:** Aflibercept
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT04684394
- **Lead sponsor:** Gemini Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-29
- **Primary completion:** 2022-01-10
- **Final completion:** 2022-02-18
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04684394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04684394, "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04684394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*